Sustained Systemic Antioxidative Effects of Intermittent Theta Burst Stimulation beyond Neurodegeneration: Implications in Therapy in 6-Hydroxydopamine Model of Parkinson's Disease

被引:1
|
作者
Zeljkovic Jovanovic, Milica [1 ]
Stanojevic, Jelena [2 ,3 ]
Stevanovic, Ivana [2 ,3 ]
Ninkovic, Milica [2 ,3 ]
Nedeljkovic, Nadezda [1 ]
Dragic, Milorad [1 ,4 ]
机构
[1] Univ Belgrade, Fac Biol, Dept Gen Physiol & Biophys, Lab Neurobiol, Belgrade 11000, Serbia
[2] Mil Med Acad, Inst Med Res, Belgrade 11000, Serbia
[3] Univ Def, Mil Med Acad, Med Fac, Belgrade 11000, Serbia
[4] Univ Belgrade, VINCA Inst Nucl Sci, Natl Inst Republ Serbia, Dept Mol Biol & Endocrinol, Belgrade 11351, Serbia
关键词
Parkinson's disease; 6-hydroxidopamine; rTMS; intermittent theta burst stimulation; oxidative stress; neuroprotection; OXIDATIVE STRESS; LIPID-PEROXIDATION; NEUROTOXICITY; GLUTATHIONE; 6-OHDA; DAMAGE; AUTOXIDATION; DOPAMINE; PATHWAYS;
D O I
10.3390/antiox13020218
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is manifested by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and caudoputamen (Cp), leading to the development of motor and non-motor symptoms. The contribution of oxidative stress to the development and progression of PD is increasingly recognized. Experimental models show that strengthening antioxidant defenses and reducing pro-oxidant status may have beneficial effects on disease progression. In this study, the neuroprotective potential of intermittent theta burst stimulation (iTBS) is investigated in a 6-hydroxydopamine (6-OHDA)-induced PD model in rats seven days after intoxication which corresponds to the occurrence of first motor symptoms. Two-month-old male Wistar rats were unilaterally injected with 6-OHDA to mimic PD pathology and were subsequently divided into two groups to receive either iTBS or sham stimulation for 21 days. The main oxidative parameters were analyzed in the caudoputamen, substantia nigra pars compacta, and serum. iTBS treatment notably mitigated oxidative stress indicators, simultaneously increasing antioxidative parameters in the caudoputamen and substantia nigra pars compacta well after 6-OHDA-induced neurodegeneration process was over. Serum analysis confirmed the systemic effect of iTBS with a decrease in oxidative markers and an increase in antioxidants. Prolonged iTBS exerts a modulatory effect on oxidative/antioxidant parameters in the 6-OHDA-induced PD model, suggesting a potential neuroprotective benefit, even though at this specific time point 6-OHDA-induced oxidative status was unaltered. These results emphasize the need to further explore the mechanisms of iTBS and argue in favor of considering it as a therapeutic intervention in PD and related neurodegenerative diseases.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
    Galindo, Maria F.
    Solesio, Maria E.
    Atienzar-Aroca, Sandra
    Zamora, Maria J.
    Jordan Bueso, Joaquin
    PARKINSONS DISEASE, 2012, 2012
  • [42] Therapeutic potential of bromelain in 6-hydroxydopamine rat model of parkinson's disease
    Cicek, B.
    Gul, M.
    Taghizadehghalehjoughi, A.
    Okkay, U.
    Yildirim, S.
    Okkay, I. F.
    Ertugrul, M. S.
    Aydin, I. C.
    Bayram, C.
    Arslan, Y. K.
    Hacimuftuoglu, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S438 - S439
  • [43] The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing
    Cannon, Jason R.
    Hua, Ya
    Richardson, Rudy J.
    Xi, Guohua
    Keep, Richard F.
    Schallert, Timothy
    BEHAVIOURAL BRAIN RESEARCH, 2007, 183 (02) : 161 - 168
  • [44] Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease
    Cindy Casteels
    Erwin Lauwers
    Guy Bormans
    Veerle Baekelandt
    Koen Van Laere
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 124 - 134
  • [45] Afobazole Restores the Dopamine Level in a 6-Hydroxydopamine Model of Parkinson’s Disease
    M. V. Voronin
    I. A. Kadnikov
    S. B. Seredenin
    Neurochemical Journal, 2019, 13 : 49 - 56
  • [46] Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease
    Morris, J. K.
    Zhang, H.
    Gupte, A. A.
    Bomhoff, G. L.
    Stanford, J. A.
    Geiger, P. C.
    BRAIN RESEARCH, 2008, 1240 : 185 - 195
  • [47] Parkinson's Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
    da Fonseca, Victor Silva
    Goncalves, Valeria de Cassia
    Izidoro, Mario Augusto
    de Almeida, Antonio-Carlos Guimaraes
    Fonseca, Fernando Luiz Affonso
    Scorza, Fulvio Alexandre
    Finsterer, Josef
    Scorza, Carla Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)
  • [48] Afobazole Restores the Dopamine Level in a 6-Hydroxydopamine Model of Parkinson's Disease
    Voronin, M. V.
    Kadnikov, I. A.
    Seredenin, S. B.
    NEUROCHEMICAL JOURNAL, 2019, 13 (01) : 49 - 56
  • [49] The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson's disease
    Abuthawabeh, Rasha
    Abuirmeileh, Amjad N.
    Alzoubi, Karem H.
    RESTORATIVE NEUROLOGY AND NEUROSCIENCE, 2020, 38 (05) : 369 - 373
  • [50] Effects of theta burst stimulation on motor cortex excitability in Parkinson's disease
    Zamir, Orit
    Gunraj, Carolyn
    Ni, Zhen
    Mazzella, Filomena
    Chen, Robert
    CLINICAL NEUROPHYSIOLOGY, 2012, 123 (04) : 815 - 821